Biowaiver for Capecitabine - FDA x EMA [Dissolution / BCS / IVIVC]

posted by Dr_Dan  – Germany, 2015-09-09 11:00 (3485 d 03:35 ago) – Posting: # 15391
Views: 11,632

Dear Mauricio
capecitabine is unstable in acidic medium and in the opinion of EMA this does not allow the BCS classification of capecitabine. IMHO this is nonsense or at least no argument against a biowaiver. Stability in acidic media is a substance specific property. The aim of a BE study is to show possible differences in formulation. If both formulation rapidly disintegrate and the API is dissolved within 15 min. what would be the advantage of a BE study? Once dissolved capecitabine from the test formulation would be affected with regard to stability in the same way as capecitabine from the reference formulation, right?
I had the same discussion with a different drug and finally the biowaiver was accepted, but it is a case by case decision. BTW I do not like the EMA product specific bioequivalence recommendations. I think These are not well elaborated.
I hope this helps.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,711 registered users;
42 visitors (0 registered, 42 guests [including 10 identified bots]).
Forum time: 13:36 CET (Europe/Vienna)

It’s easy to lie with statistics;
it is easier to lie without them.    Frederick Mosteller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5